NATCO Pharma Limited

NSEI:NATCOPHARM Stock Report

Market Cap: ₹182.4b

NATCO Pharma Dividend

Dividend criteria checks 4/6

NATCO Pharma is a dividend paying company with a current yield of 0.94% that is well covered by earnings.

Key information

0.9%

Dividend yield

13%

Payout ratio

Industry average yield0.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share₹71.34
Dividend yield forecast in 3Y1.1%

Recent dividend updates

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12
NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Recent updates

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Apr 03
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Feb 21
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18
NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17
NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13
Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30
An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12
Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12
NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16
Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20
NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20
Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12
NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02
Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 22
NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year

Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Feb 16
Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden

Nov 30
Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 24
Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well

Mar 22
These 4 Measures Indicate That NATCO Pharma (NSE:NATCOPHARM) Is Using Debt Reasonably Well

Should NATCO Pharma Limited (NSE:NATCOPHARM) Be Part Of Your Dividend Portfolio?

Mar 04
Should NATCO Pharma Limited (NSE:NATCOPHARM) Be Part Of Your Dividend Portfolio?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: NATCOPHARM's dividend payments have been volatile in the past 10 years.

Growing Dividend: NATCOPHARM's dividend payments have increased over the past 10 years.


Dividend Yield vs Market

NATCO Pharma Dividend Yield vs Market
How does NATCOPHARM dividend yield compare to the market?
SegmentDividend Yield
Company (NATCOPHARM)0.9%
Market Bottom 25% (IN)0.3%
Market Top 25% (IN)1.2%
Industry Average (Pharmaceuticals)0.7%
Analyst forecast in 3 Years (NATCOPHARM)1.1%

Notable Dividend: NATCOPHARM's dividend (0.94%) is higher than the bottom 25% of dividend payers in the Indian market (0.26%).

High Dividend: NATCOPHARM's dividend (0.94%) is low compared to the top 25% of dividend payers in the Indian market (1.18%).


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (13.4%), NATCOPHARM's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (32.5%), NATCOPHARM's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.